Compare Adaptive Biotechnologies Corp (ADPT) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Nasdaq Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Nasdaq Inc trades at $85.1 (market cap $48.88B). The key difference: Nasdaq Inc is far larger — about 14.7× Adaptive Biotechnologies Corp's market cap, and Nasdaq Inc pays a 1.3% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NDAQ | |
|---|---|---|
Market Cap | $3.33B | $48.88B |
Sector | Health | Financials |
52-Week High | $22.37 | $100.98 |
52-Week Low | $10.24 | $76.85 |
Enterprise Value | $3.19B | $55.94B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Nasdaq (NDAQ) trades at $86.43, up 2.09% with strong fundamental performance including 2025 revenue of $8.26B and net income of $1.79B. The stock shows bullish technical signals with support at $83 and resistance at $86, while maintaining consistent earnings beats in recent quarters. Recent news highlights Nasdaq's record trading volumes and strategic expansions.
Outlook remains positive with analyst consensus target of $103 (19% upside), though risks include market volatility sensitivity and competitive pressures. The company's dominant exchange position and growing IPO pipeline provide solid growth foundation for investors seeking financial services exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
